Mallinckrodt to acquire Cadence Pharmaceuticals for $14.00 per share in cash
MLex Summary: NYSE-listed Irish specialty pharmaceuticals company Mallinckrodt has agreed to acquire Nasdaq-listed biopharmaceutical company Cadence Pharmaceuticals for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis. The deal is expected to be completed in mid- to late-March...To view the full article, register now.
Already a subscriber? Click here to view full article